On Oct 19, major Wall Street analysts update their ratings for $Aura Biosciences (AURA.US)$, with price targets ranging from $20 to $24.
Evercore analyst Liisa Bayko maintains with a buy rating, and maintains the target price at $20.
TD Cowen analyst Phil Nadeau maintains with a buy rating.
BTIG analyst Julian Harrison maintains with a buy rating, and adjusts the target price from $21 to $24.
H.C. Wainwright analyst Edward White maintains with a buy rating, and adjusts the target price from $21 to $22.
Scotiabank analyst George Farmer maintains with a buy rating, and adjusts the target price from $20 to $23.
Furthermore, according to the comprehensive report, the opinions of $Aura Biosciences (AURA.US)$'s main analysts recently are as follows:
The early data from the ongoing Phase 1 trial for non-muscle invasive bladder cancer indicate that bel-sar has a consistent abscopal effect with broad immune infiltration. This is seen as a precursor to potential durable clinical remissions observable at later stages in future studies. Given that 70% to 80% of non-muscle invasive bladder cancer patients experience recurrence under the current standard of care, there exists a significant unmet need and opportunity for differentiation.
Here are the latest investment ratings and price targets for $Aura Biosciences (AURA.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
